Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials-Reference-Cited by-同舟云学术

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials

Published:2019-04-11 Issue:1 Volume:181 Page:80-87
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Silverberg J.I.¹^ORCID,Simpson E.L.²,Ardeleanu M.³,Thaçi D.⁴,Barbarot S.⁵^ORCID,Bagel J.⁶,Chen Z.³,Eckert L.⁷^ORCID,Chao J.³,Korotzer A.³,Rizova E.⁸,Rossi A.B.⁸^ORCID,Lu Y.³,Graham N.M.H.³,Hultsch T.⁸,Pirozzi G.⁹,Akinlade B.³

Affiliation:

1. Department of Dermatology, Preventive Medicine and Medical Social Sciences Northwestern University Feinberg School of Medicine NMH/Arkes Family Pavilion Suite 1600, 676 N. Saint Clair Chicago IL 60611 U.S.A.

2. Department of Dermatology Oregon Health & Science University Portland OR U.S.A.

3. Regeneron Pharmaceuticals, Inc. Tarrytown NY U.S.A.

4. University of Lübeck Lübeck Germany

5. Service de Dermatologie Centre Hospitalier Universitaire (CHU) de Nantes Nantes France

6. Eczema Treatment Center of Central New Jersey East Windsor NJ U.S.A.

7. Sanofi Chilly‐Mazarin France

8. Sanofi Genzyme Cambridge MA U.S.A.

9. Sanofi Bridgewater NJ U.S.A.

Funder

Regeneron Pharmaceuticals

Sanofi

Publisher